Encapsulated diagnostics and therapeutics in nanoparticles—conjugated to tropic cells and methods for their use

US10426801B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10426801-B2
Application numberUS-201414256777-A
CountryUS
Kind codeB2
Filing dateApr 18, 2014
Priority dateOct 18, 2011
Publication dateOct 1, 2019
Grant dateOct 1, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.

First claim

Opening claim text (preview).

What is claimed is: 1. A therapeutic delivery vehicle comprising a gold particle coated with a cationic thiol moiety internalized by a genetically modified neural stem cell, wherein the cationic thiol moiety is 11-mercaptoundecyltrimethylammonium bromide. 2. The therapeutic delivery vehicle of claim 1 , wherein the genetically modified neural stem cell is an immortalized neural stem cell. 3. The therapeutic delivery vehicle of claim 1 , wherein the genetically modified neural stem cell expresses cytosine deaminase, v-myc, or both cytosine deaminase and v-myc. 4. The therapeutic delivery vehicle of claim 1 , wherein the gold particle is a gold nanorod. 5. The therapeutic delivery vehicle of claim 1 , wherein the average longest dimension of the gold particle is about 41 nm. 6. The therapeutic delivery vehicle of claim 1 , wherein the gold particle is about 10 nm by about 41 nm.

Assignees

Inventors

Classifications

  • conjugated systems · CPC title

  • the form being a nanoparticle, e.g. an immuno-nanoparticle · CPC title

  • Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors · CPC title

  • A61K35/30Primary

    Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue · CPC title

  • the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10426801B2 cover?
A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particl…
Who is the assignee on this patent?
Hope City
What technology area does this patent fall under?
Primary CPC classification A61K35/30. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).